ESTROGEN/PROGESTERONE RECEPTOR NEGATIVITY AND HER2 POSITIVITY PREDICT LOCOREGIONAL RECURRENCE IN PATIENTS WITH T1a,bN0 BREAST CANCER

Albert J. M., Gonzalez-Angulo A. M., Guray M., Sahin A., Strom E. A., Tereffe W., ...Daha Fazla

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, cilt.77, sa.5, ss.1296-1302, 2010 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 77 Sayı: 5
  • Basım Tarihi: 2010
  • Doi Numarası: 10.1016/j.ijrobp.2009.12.011
  • Dergi Adı: INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1296-1302
  • Anahtar Kelimeler: HER2, estrogen receptor, ER, progesterone receptor, PR, local recurrence, locoregional recurrence, DOXORUBICIN-BASED CHEMOTHERAPY, SURGICAL ADJUVANT BREAST, LOCAL RECURRENCE, BOWEL PROJECT, TRASTUZUMAB, OVEREXPRESSION, AMPLIFICATION, EXPRESSION, PROGNOSIS, SURVIVAL
  • Dokuz Eylül Üniversitesi Adresli: Hayır

Özet

Purpose: Data have suggested that the molecular features of breast cancer are important determinants of outcome; however, few studies have correlated these features with locoregional recurrence (LRR). In the present study, we evaluated estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) as predictors of LRR in patients with lymph node-negative disease and tumors <= 1 cm, because these patients often do not receive adjuvant chemotherapy or trastuzumab.